Upcoming IPO: Molbio Diagnostics files DRHP with SEBI for IPO

Temasek and Motilal Oswal Private Equity-backed Molbio Diagnostics has filed its Draft Red Herring Prospectus (DRHP) on August 22, 2025, with the Securities and Exchange Board of India (SEBI) for an initial public offering (IPO).

IPO Structure and Details

• The proposed issue is a combination of a fresh issue of up to ₹200 crore and an offer-for-sale (OFS) of up to 1.25 crore shares by existing shareholders, V Sciences Investments Pte. Ltd., Exxora Trading LLP, India Business Excellence Fund III, Dr. Chandrasekhar Bhaskaran Nair (1), and Gopalkrishna Mangalore Kini. 
• Book-running lead managers for the IPO are Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited, and Motilal Oswal Investment Advisors Limited. 
• KFin Technologies Limited is the registrar for the issue. 

Check out newly Listed IPOs on BSE and NSE.

Utilisation of Funds

Molbio Diagnostics intends to deploy the net proceeds from the fresh issue towards the following purposes:

• Investment in capital expenditure for establishing infrastructure related to the research and development centre, the Center of Excellence, along with associated office facilities
• Purchase of plant, machinery, and various equipment required for our manufacturing units located in Goa (Unit I and Unit II) and Visakhapatnam
• General corporate purposes 

Explore other Upcoming IPOs on BSE and NSE.

Financial Performance

Molbio Diagnostics has demonstrated consistent growth in its revenue from operations, increasing from ₹332.46 crore in FY 2022–23 to ₹836.56 crore in FY 2023–24 and further to ₹1,020.42 crore in FY 2024–25. 

Also, the company has shown a strong turnaround in profitability, from a restated loss of ₹3.45 crore in FY 2022–23 to a profit of ₹83.54 crore in FY 2023–24 and ₹138.58 crore in FY 2024–25. 

Company Profile 

Molbio Diagnostics is a point-of-care (“POC”) molecular diagnostics company. They have developed a ‘Truenat’ platform, a proprietary POC real-time PCR system designed to function efficiently in decentralised and resource-limited settings.

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory. 

To read the RA disclaimer, please click here.